Company
Headquarters: Bridgewater, NJ, United States
Employees: 613
CEO: Mr. William H. Lewis J.D., M.B.A.
$37.77 Billion
USD as of Jan. 1, 2026
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
| Last Financial Reports Date | Sept. 30, 2025 |
| Revenue TTM | $447.0 M |
| EBITDA | $-978,790,016 |
| Gross Profit TTM | $342.2 M |
| Profit Margin | -264.83% |
| Operating Margin | -183.61% |
| Quarterly Revenue Growth | 52.40% |
Insmed Incorporated has the following listings and related stock indices.
Stock: NASDAQ: INSM
Stock: FSX: IM8N